title: [Thrombotic microangiopathies. Incidence, pathogenesis, diagnosis, treatment and prognosis].
abstract: BACKGROUND
  The objective of this work was to review current data about the pathophysiology, clinical features, and treatment of thrombotic microangiopathies.
  
  
  BACKGROUND
  Thrombotic microangiopathies are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes. In thrombotic thrombocytopenic purpura, systemic microvascular aggregation of platelets causes ischemia in the brain and other organs. In the hemolytic-uremic syndrome, platelet-fibrin thrombi occlude predominantly the renal circulation. Thrombotic microangiopathy is a rare disorder whose varied clinical manifestations result from the formation of platelet-rich thrombi within the microvasculature and consequent tissue ischemia. The clinical features are acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. This diagnosis is of considerable importance because of the possible fulminant clinical course. Some atypical forms may be unrecognized. Plasma exchange is the current reference treatment of thrombotic thrombocytopenic purpura. However, in the light of recent publications, either infusions of concentrates of purified enzyme or more intensive immunosuppressive therapy would be more specific.
authors.affiliation: Service de réanimation médicale, CHU Habib-Bourguiba, route El-Ain-Km 1, 3029 Sfax, Tunisie. bahloulmab@yahoo.fr
authors.forename: M
authors.initials: M
authors.lastname: Bahloul
authors.forename: H
authors.initials: H
authors.lastname: Dammak
authors.forename: H
authors.initials: H
authors.lastname: Kallel
authors.forename: N
authors.initials: N
authors.lastname: Khlaf-Bouaziz
authors.forename: C
authors.initials: C
authors.lastname: Ben Hamida
authors.forename: A
authors.initials: A
authors.lastname: Chaari
authors.forename: H
authors.initials: H
authors.lastname: Chelly
authors.forename: N
authors.initials: N
authors.lastname: Rekik
authors.forename: M
authors.initials: M
authors.lastname: Bouaziz
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008833:Microcirculation / Q000502:physiology*; D011379:Prognosis; D013927:Thrombosis / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin